

**Mice Model Market by Model Type (Inbred, Outbred, Hybrid), Service (Breeding, Rederivation), Application (Personalized Medicine), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology), End User (CROs) - Global Forecast to 2030**

Market Report | 2025-08-12 | 446 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The mice model market is projected to reach USD 2.74 billion by 2030 from USD 1.70 billion in 2025, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by several factors, such as rising adoption of mice models in preclinical studies due to genetic & physiological versatility; the increasing demand for mouse clinical trials (MCTs); the rising demand for personalized medicine in oncology; and advancements in genetic engineering. Utilization of CRISPR in biomedical research and the increasing demand for disease-specific models are also expected to contribute to market growth during the forecast period.

<https://www.marketsandmarkets.com/Images/mice-model-market-Overview.webp>

By model type, the inbred mice segment accounted for the largest share of the market in 2024.

The market is segmented by model type into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. In 2024, the inbred mice segment accounted for the largest share of the mice model market. The large share of the inbred mice segment is attributed to the ability of inbred strains to provide genetic uniformity for preclinical studies, standardized breeding protocols that enable scalable production, and supply chains that support continuous availability. Regulatory frameworks at national and international levels recognize inbred strains as reference models for efficacy and safety assessment, and centralized breeding facilities implement quality control measures to maintain strain integrity. Adoption of inbred mice spans pharmaceutical and biotechnology companies and academic and government research institutions, where controlled genetic backgrounds reduce experimental variability.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

By application, the drug discovery & development segment accounted for the largest share of the market in 2024. The mice model market is segmented into drug discovery & development, research applications, and personalized medicine. In 2024, the drug discovery & development segment accounted for the largest share of the market. Mouse models are deployed in target validation assays to confirm the relevance of molecular targets, in lead optimization studies to compare pharmacodynamic profiles, and in efficacy evaluations to measure treatment responses under controlled conditions. Safety pharmacology protocols-cardiovascular, respiratory, and central nervous system endpoints-rely on telemetry recordings and behavioral assays conducted in mice. At the same time, reproductive and developmental toxicity assessments use timed-pregnancy protocols to determine embryonic viability and teratogenic risk. Histopathological examinations and clinical chemistry analyses of tissue samples support regulatory submissions, and omics profiling (transcriptomics, proteomics, metabolomics) informs dose selection and mechanism-of-action studies. Service providers integrate these applications into end-to-end workflows for end users. Combined, these integrated applications ensure the dominance of drug discovery & development applications in the mice model market.

By region, North America accounted for the largest share of the mice model market in 2024. In 2024, North America accounted for the largest share of the mice model market due to the concentration of major contract research organizations and breeding suppliers, government and private funding mechanisms, and a regulatory environment emphasizing standardized preclinical practices. The key market players, such as Charles River Laboratories (US), The Jackson Laboratory (US), and Inotiv (US), have their presence in the region, thus ensuring regional supply and technical support. Public funding agencies such as the National Institutes of Health (NIH) allocate substantial budgets to basic & translational research, while pharmaceutical & biotechnology companies commit a significant portion of R&D expenditure to preclinical in vivo models. Academic research institutions and specialized contract research organizations leverage this infrastructure and funding landscape to conduct target validation, toxicology, and efficacy studies, reinforcing North America's large share in the global mice model market.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
  - By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
  - By Region: North America -45%, Europe - 20%, the Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%
- Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan) Harbour BioMed (China), genOway (France), GemPharmatech (China), Cyagen (US), Ozgene Pty Ltd (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Vivo Bio Tech Ltd (India), ingenious targeting laboratory (US), Janvier Labs (France), Champions Oncology, Inc (US), and Vitalstar Biotechnology Co., Ltd. (China) are some of the key companies offering mice model products & services.

#### Research Coverage:

This research report categorizes the mice model market by model type & service [model types (inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice, breeding services, cryopreservation services, rederivation services, quarantine services, and other services)], by application (drug discovery & development, research applications, and personalized medicine), by technology (CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies), by therapeutic area (oncology, neurology, immunology, metabolic diseases, cardiovascular diseases, and other therapeutic areas), by product end user (pharmaceutical & biotechnology companies, academic & research Institutes, and CROs & CDMOs), by services end user (pharmaceutical & biotechnology companies, government & biomedical research institutes, and CDMOs), and by region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the mice model market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

launches, acquisitions, and recent developments associated with the mice model market. This report covers the competitive analysis of upcoming startups in the mice model market ecosystem.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the mice model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following :

- Analysis of key drivers (high adoption of mice models in preclinical studies, the increasing demand for mouse clinical trials, the rising demand for personalized medicine in oncology, technological advancements in genetic engineering), restraints (the introduction of 3D printed models, ethical concerns, and regulatory restrictions), opportunities (Utilization of CRISPR in biomedical research, and the rising demand for disease-specific models), and challenges (development of alternative animal testing methods and genetic & phenotypic variability).
- Product approvals: Detailed insights into newly approved products of the mice models market.
- Market development: Comprehensive information about lucrative markets - the report analyses the mice model market across varied regions.
- Market diversification: Exhaustive information about new products, recent developments, and investments in the mice model market.
- Pipeline analysis: Comprehensive information about products under clinical trials.
- Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), and Biocytogen (China).

#### Table of Contents:

1	INTRODUCTION	40
1.1	STUDY OBJECTIVES	40
1.2	MARKET DEFINITION	40
1.3	MARKET SCOPE	41
1.3.1	INCLUSIONS & EXCLUSIONS	41
1.3.2	MARKETS & REGIONS COVERED	42
1.3.3	YEARS CONSIDERED	43
1.3.4	CURRENCY CONSIDERED	43
1.4	STAKEHOLDERS	43
1.5	SUMMARY OF CHANGES	44
2	RESEARCH METHODOLOGY	45
2.1	RESEARCH DATA	45
2.1.1	SECONDARY DATA	46
2.1.2	PRIMARY DATA	46
2.2	MARKET ESTIMATION METHODOLOGY	47
2.2.1	BOTTOM-UP APPROACH	48
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	50
2.3	TOP-DOWN APPROACH	50
2.4	GROWTH FORECAST	52
2.5	MARKET BREAKDOWN AND DATA TRIANGULATION	53
2.6	RESEARCH ASSUMPTIONS	54
2.7	LIMITATIONS	54

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.8	MARKET FORECAST	55
2.9	RISK ANALYSIS	55
3	EXECUTIVE SUMMARY	56
4	PREMIUM INSIGHTS	60
4.1	MICE MODEL MARKET OVERVIEW	60
4.2	NORTH AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE (2024)	61
4.3	MICE MODEL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	61
4.4	MICE MODEL MARKET, BY MODEL TYPE (END USER), 2025 VS. 2030	62
4.5	MICE MODEL MARKET SHARE, BY SERVICES (END USER)	62
	?	
5	MARKET OVERVIEW	63
5.1	INTRODUCTION	63
5.2	MARKET DYNAMICS	63
5.2.1	DRIVERS	64
5.2.1.1	High adoption of mice models in preclinical studies	64
5.2.1.2	Increasing demand for Mouse Clinical Trials (MCTs)	65
5.2.1.3	Growing preference for personalized medicine in oncology	66
5.2.1.4	Advancements in genetic engineering	67
5.2.2	RESTRAINTS	67
5.2.2.1	Introduction of 3D printed models	67
5.2.2.2	Ethical concerns and regulatory restrictions	68
5.2.3	OPPORTUNITIES	69
5.2.3.1	Utilization of CRISPR in biomedical research	69
5.2.3.2	Rising demand for disease-specific models	69
5.2.4	CHALLENGES	70
5.2.4.1	Development of alternative animal testing methods	70
5.2.4.2	Genetic & phenotypic variability	71
5.3	MICE MODEL MARKET LANDSCAPE	71
5.3.1	HISTORY OF MICE MODELS	71
5.3.2	MICE MODEL GENERATION PROCESS	72
5.3.3	TECHNIQUES FOR MICE MODEL DEVELOPMENT	72
5.3.4	TECHNOLOGICAL ADVANCEMENTS	73
5.3.5	CONSIDERATIONS FOR MICE MODEL DEVELOPMENT	74
5.4	VALUE CHAIN ANALYSIS	75
5.5	PRICING ANALYSIS	76
5.5.1	AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024	76
5.5.2	AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION, 2024	78
5.6	ECOSYSTEM ANALYSIS	79
5.6.1	MICE MODEL VENDORS	79
5.6.2	MICE MODEL SERVICE VENDORS	80
5.6.3	MICE MODEL END USERS	80
5.6.4	REGULATORY ORGANIZATIONS	81
5.7	TECHNOLOGY ANALYSIS	82
5.7.1	KEY TECHNOLOGIES	82
5.7.1.1	CRISPR/CAS9 gene editing	82
5.7.1.2	Pronuclear Microinjection (PNI)	82
5.7.1.3	Embryo cryopreservation & assisted reproduction	83

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.7.2	COMPLEMENTARY TECHNOLOGIES	83
5.7.2.1	Multimodal preclinical imaging	83
5.7.2.2	Automated behavioural phenotyping	84
5.7.2.3	Integrated physiological monitoring	84
5.7.3	ADJACENT TECHNOLOGIES	84
5.7.3.1	Ex vivo CRISPR screening in cell culture	84
5.7.3.2	High-content bioinformatics pipeline	85
5.7.3.3	Mass spectroscopy-based tissue profiling	85
5.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	86
5.9	PATENT ANALYSIS	87
5.9.1	METHODOLOGY	87
5.9.2	PATENTS FILED, BY DOCUMENT TYPE, 2014-2024	87
5.10	TRADE DATA ANALYSIS	89
5.10.1	IMPORT DATA	89
5.10.2	IMPORT DATA	90
5.11	KEY CONFERENCES & EVENTS	91
5.11.1	KEY CONFERENCES & EVENTS (2025-2026)	91
5.12	TARIFF & REGULATORY LANDSCAPE	92
5.12.1	TARIFF DATA (HS CODE 106.19.90)	92
5.12.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	93
5.12.3	REGULATORY FRAMEWORK	97
5.12.3.1	North America	97
5.12.3.2	Europe	98
5.12.3.3	China	100
5.12.3.4	Japan	100
5.12.3.5	India	101
5.12.3.6	Australia	102
5.12.3.7	Brazil	102
5.13	PORTER'S FIVE FORCES ANALYSIS	103
5.13.1	THREAT OF NEW ENTRANTS	104
5.13.2	THREAT OF SUBSTITUTES	104
5.13.3	BARGAINING POWER OF BUYERS	104
5.13.4	BARGAINING POWER OF SUPPLIERS	104
5.13.5	INTENSITY OF COMPETITIVE RIVALRY	104
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	105
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	105
5.14.2	ROLE OF STAKEHOLDERS IN BUYING PROCESS	105
5.14.3	BUYING CRITERIA FOR MICE MODEL MARKET	106
5.15	INVESTMENT & FUNDING SCENARIO	107
5.16	IMPACT OF GENERATIVE AI ON MICE MODEL MARKET	108
5.16.1	AI-USE CASES	108
5.16.2	KEY COMPANIES IMPLEMENTING AI	109
?		
5.17	CASE STUDIES	109
5.17.1	CASE STUDY 1: AAV GENE EDITING IN CYAGEN LDLR MUTANT MICE AMELIORATES ATHEROSCLEROSIS	109
5.17.2	CASE STUDY 2: METABOLIC EFFECTS OF SEMAGLUTIDE & TIRZEPATIDE IN DIET-INDUCED OBESE (DIO) MICEBAC	109
5.17.3	CASE STUDY 3: TARGETING NATURAL KILLER CELL ACTIVITY WITH HUMANIZED NSG-IL15 MOUSE MODEL	110

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.18	TRUMP TARIFF IMPACT ON MICE MODEL MARKET	110
5.18.1	KEY TARIFF RATES	110
5.18.2	PRICE IMPACT ANALYSIS	112
5.18.3	KEY IMPACT ON VARIOUS REGIONS	112
5.18.3.1	US	112
5.18.3.2	Europe	112
5.18.3.3	Asia Pacific	113
5.18.3.4	Rest of the World	113
5.18.4	END-USE INDUSTRY IMPACT	113
5.18.4.1	Pharmaceutical & biotechnology companies	113
5.18.4.2	CROs & CDMOs	114
5.18.4.3	Academic & research institutes	114
6	MICE MODEL MARKET, BY MODEL TYPE & SERVICE	115
6.1	INTRODUCTION	116
6.2	MODEL TYPE	116
6.2.1	INBRED MICE	119
6.2.1.1	High utilization across research applications to propel market	119
6.2.2	GENETICALLY ENGINEERED MICE	122
6.2.2.1	Ability to induce mutations for CVD & cancer research to drive market	122
6.2.3	HYBRID/CONGENIC MICE	125
6.2.3.1	Growing focus on biomedical research to boost demand	125
6.2.4	OUTBRED MICE	128
6.2.4.1	Genetic diversity benefits to support market growth	128
6.3	SERVICES	131
6.3.1	BREEDING SERVICES	134
6.3.1.1	Customization of models for specific research applications to boost demand	134
6.3.2	CRYOPRESERVATION SERVICES	137
6.3.2.1	Rising focus on preservation of novel mice models to propel market	137
6.3.3	REDERIVATION SERVICES	140
6.3.3.1	Stringent quality assurance standards to fuel market	140
6.3.4	QUARANTINE SERVICES	143
6.3.4.1	Rising demand for germ-free mice to support market growth	143
6.3.5	OTHER SERVICES	146
?		
7	MICE MODEL MARKET, BY TECHNOLOGY	150
7.1	INTRODUCTION	151
7.2	CRISPR/CAS9	151
7.2.1	ADVANTAGES SUCH AS SIMPLIFIED DESIGN AND COST EFFICIENCY TO PROPEL MARKET	151
7.3	MICROINJECTIONS	155
7.3.1	LOW TOXICITY AND HIGH SUCCESS RATE TO DRIVE MARKET	155
7.4	EMBRYONIC STEM CELL INJECTIONS	158
7.4.1	INCREASING DEMAND FOR TARGETED MICE MODELS IN IMMUNOLOGICAL RESEARCH TO FUEL MARKET	158
7.5	NUCLEAR TRANSFER TECHNIQUE	161
7.5.1	POTENTIAL TO PRODUCE IDENTICAL MICE TO DRIVE MARKET	161
7.6	OTHER TECHNOLOGIES	164
8	MICE MODEL MARKET, BY APPLICATION	167
8.1	INTRODUCTION	168

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.2	DRUG DISCOVERY & DEVELOPMENT	168
8.2.1	INCREASING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET	168
8.3	RESEARCH APPLICATIONS	172
8.3.1	INCREASING FUNDING INVESTMENTS FOR CANCER RESEARCH TO DRIVE MARKET	172
8.4	PERSONALIZED MEDICINE	175
8.4.1	INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH	175
9	MICE MODEL MARKET, BY THERAPEUTIC AREA	179
9.1	INTRODUCTION	180
9.2	ONCOLOGY	180
9.2.1	GROWING FOCUS ON THERAPEUTIC DEVELOPMENT TO PROPEL MARKET	180
9.3	METABOLIC DISEASES	184
9.3.1	INCREASING PREVALENCE OF ENDOCRINE DISORDERS TO DRIVE MARKET	184
9.4	IMMUNOLOGY	187
9.4.1	RISING CLINICAL RESEARCH ACTIVITIES FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET	187
9.5	NEUROLOGY	190
9.5.1	INCREASING INVESTMENTS IN R&D FOR CNS DISEASES TO BOOST DEMAND	190
9.6	CARDIOVASCULAR DISEASES	193
9.6.1	GROWING FOCUS ON TARGETED TREATMENTS FOR CVD TO BOOST DEMAND	193
9.7	OTHER THERAPEUTIC AREAS	196
	?	
10	MICE MODEL TYPE MARKET, BY END USER	200
10.1	INTRODUCTION	201
10.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	201
10.2.1	RISING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO FUEL MARKET	201
10.3	CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CROS & CDMOS)	205
10.3.1	INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE MARKET	205
10.4	ACADEMIC & RESEARCH INSTITUTES	208
10.4.1	INCREASING FUNDING INITIATIVES FOR LIFE SCIENCES R&D TO SUPPORT MARKET GROWTH	208
11	MICE MODEL SERVICES MARKET, BY END USER	211
11.1	INTRODUCTION	212
11.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	212
11.2.1	RISING OUTSOURCING OF PRECLINICAL SERVICES TO PROPEL MARKET	212
11.3	CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS)	215
11.3.1	DEVELOPMENT OF INTEGRATED MODELS AND GROWTH IN BIOLOGICS TO BOOST DEMAND	215
11.4	GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES	218
11.4.1	FOCUS ON TRANSLATIONAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH	218
12	MICE MODEL MARKET, BY REGION	222
12.1	INTRODUCTION	223
12.2	NORTH AMERICA	223
12.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	223
12.2.2	US	228
12.2.2.1	Rising production of monoclonal antibodies to fuel market	228
12.2.3	CANADA	232
12.2.3.1	Growth in stem cell research activities to fuel market	232
12.3	EUROPE	235
12.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	235

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.3.2	GERMANY	240
12.3.2.1	Growth in biotechnology industry to drive market	240
12.3.3	UK	243
12.3.3.1	Increasing focus on cancer research to propel market	243
12.3.4	FRANCE	246
12.3.4.1	Rising investments in proteomics & genomics research to boost demand	246
12.3.5	ITALY	249
12.3.5.1	Growth in pharmaceutical & biotechnology industry to drive market	249
	?	
12.3.6	SPAIN	252
12.3.6.1	Extensive R&D pipeline to fuel uptake	252
12.3.7	REST OF EUROPE	256
12.4	ASIA PACIFIC	259
12.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	259
12.4.2	CHINA	265
12.4.2.1	Favorable investments in life sciences research to drive market	265
12.4.3	JAPAN	268
12.4.3.1	Increasing focus on personalized diagnostics products to drive market	268
12.4.4	INDIA	272
12.4.4.1	Favorable initiatives for drug discovery & development to boost market	272
12.4.5	AUSTRALIA	275
12.4.5.1	High number of research institutes to favor market growth	275
12.4.6	SOUTH KOREA	278
12.4.6.1	Innovation in health & biotech sectors to support market uptake	278
12.4.7	REST OF ASIA PACIFIC	281
12.5	LATIN AMERICA	285
12.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	285
12.5.2	BRAZIL	289
12.5.2.1	Increasing investments in biopharmaceutical research to fuel uptake	289
12.5.3	MEXICO	292
12.5.3.1	Expanding healthcare ecosystem to support market growth	292
12.5.4	REST OF LATIN AMERICA	295
12.6	MIDDLE EAST	299
12.6.1	MACROECONOMIC OUTLOOK IN MIDDLE EAST	299
12.6.2	GCC COUNTRIES	303
12.6.2.1	Kingdom of Saudi Arabia (KSA)	306
12.6.2.1.1	Growing focus on advancement of healthcare sector to boost market	306
12.6.2.2	United Arab Emirates	310
12.6.2.2.1	Increasing R&D activities and growing demand for personalized medicine to propel market	310
12.6.2.3	Other GCC Countries	314
12.6.3	REST OF MIDDLE EAST	317
12.7	AFRICA	321
12.7.1	RIISING PRECISION MEDICINE INITIATIVES TO SUPPORT MARKET GROWTH	321
12.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	321
	?	
13	COMPETITIVE LANDSCAPE	325
13.1	OVERVIEW	325

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2	KEY PLAYERS STRATEGIES/RIGHT TO WIN	325
13.2.1	STRATEGIES ADOPTED BY KEY PLAYERS IN MICE MODEL MARKET, 2022-2025	326
13.3	REVENUE SHARE ANALYSIS, 2022?2024	328
13.4	MARKET SHARE ANALYSIS	328
13.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	331
13.5.1	STARS	331
13.5.2	EMERGING LEADERS	331
13.5.3	PERVASIVE PLAYERS	331
13.5.4	PARTICIPANTS	331
13.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	333
13.5.5.1	Company footprint	333
13.5.5.2	Region footprint	334
13.5.5.3	Model type & service footprint	335
13.5.5.4	Application footprint	336
13.5.5.5	Technology footprint	337
13.5.5.6	Therapeutic area footprint	338
13.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	339
13.6.1	PROGRESSIVE COMPANIES	339
13.6.2	RESPONSIVE COMPANIES	339
13.6.3	DYNAMIC COMPANIES	339
13.6.4	STARTING BLOCKS	339
13.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	341
13.6.5.1	Detailed list of key startups/SME players	341
13.6.5.2	Competitive benchmarking of key startups/SMEs	342
13.7	COMPANY VALUATION & FINANCIAL METRICS	343
13.7.1	FINANCIAL METRICS	343
13.7.2	COMPANY VALUATION	343
13.8	BRAND/PRODUCT COMPARATIVE ANALYSIS	344
13.8.1	BRAND/PRODUCT COMPARATIVE ANALYSIS FOR MICE MODEL MARKET	344
13.9	COMPETITIVE SCENARIO	345
13.9.1	PRODUCT/SERVICE LAUNCHES	345
13.9.2	DEALS	345
13.9.3	EXPANSIONS	349
13.9.4	OTHER DEVELOPMENTS	351
?		
14	COMPANY PROFILES	352
14.1	KEY PLAYERS	352
14.1.1	CHARLES RIVER LABORATORIES	352
14.1.1.1	Business overview	352
14.1.1.2	Products/Services offered	353
14.1.1.3	Recent developments	356
14.1.1.3.1	Deals	356
14.1.1.3.2	Expansions	357
14.1.1.3.3	Other developments	358
14.1.1.4	MnM view	358
14.1.1.4.1	Key strengths	358
14.1.1.4.2	Strategic choices	358

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.1.4.3	Weaknesses & competitive threats	358
14.1.2	THE JACKSON LABORATORY	359
14.1.2.1	Business overview	359
14.1.2.2	Products/Services offered	360
14.1.2.3	Recent developments	366
14.1.2.3.1	Deals	366
14.1.2.3.2	Expansions	367
14.1.2.4	MnM view	368
14.1.2.4.1	Key strengths	368
14.1.2.4.2	Strategic choices	368
14.1.2.4.3	Weaknesses & competitive threats	368
14.1.3	INOTIV	369
14.1.3.1	Business overview	369
14.1.3.2	Products/Services offered	370
14.1.3.3	Recent developments	373
14.1.3.3.1	Deals	373
14.1.3.3.2	Expansions	374
14.1.3.4	MnM view	374
14.1.3.4.1	Key strengths	374
14.1.3.4.2	Strategic choices	374
14.1.3.4.3	Weaknesses & competitive threats	374
14.1.4	SR CORPORATION	375
14.1.4.1	Business overview	375
14.1.4.2	Product/Services offered	376
14.1.4.3	Recent developments	378
14.1.4.3.1	Deals	378
14.1.4.3.2	Expansions	378
14.1.4.4	MnM view	379
14.1.4.4.1	Key strengths	379
14.1.4.4.2	Strategic choices	379
14.1.4.4.3	Weaknesses & competitive threats	379
14.1.5	BIOCYTOGEN	380
14.1.5.1	Business overview	380
14.1.5.2	Product/Services offered	381
14.1.5.3	Recent developments	383
14.1.5.3.1	Product/Service launches	383
14.1.5.3.2	Deals	383
14.1.5.3.3	Expansions	385
14.1.5.4	MnM view	385
14.1.5.4.1	Key strengths	385
14.1.5.4.2	Strategic choices	385
14.1.5.4.3	Weaknesses & competitive threats	386
14.1.6	SHANGHAI MODEL ORGANISMS CENTER, INC.	387
14.1.6.1	Business overview	387
14.1.6.2	Product/Services offered	388
14.1.6.3	Recent developments	389
14.1.6.3.1	Deals	389

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.7	TRANS GENIC INC.	390
14.1.7.1	Business overview	390
14.1.7.2	Products/Services offered	391
14.1.7.3	Recent developments	392
14.1.7.3.1	Deals	392
14.1.8	HARBOUR BIOMED	393
14.1.8.1	Business overview	393
14.1.8.2	Product/Services offered	394
14.1.8.3	Recent developments	395
14.1.8.3.1	Deals	395
14.1.8.3.2	Other developments	397
14.1.9	GENOWAY	398
14.1.9.1	Business overview	398
14.1.9.2	Product/Services offered	399
14.1.9.3	Recent developments	401
14.1.9.3.1	Deals	401
14.1.10	GEMPHARMATECH	402
14.1.10.1	Business overview	402
14.1.10.2	Product/Services offered	403
14.1.10.3	Recent developments	404
14.1.10.3.1	Product/Service launches	404
14.1.10.3.2	Deals	405
14.1.10.3.3	Expansions	405
?		
14.1.11	CYAGEN	406
14.1.11.1	Business overview	406
14.1.11.2	Product/Services offered	406
14.1.11.3	Recent developments	407
14.1.11.3.1	Deals	407
14.1.12	OZGENE PTY LTD.	408
14.1.12.1	Business overview	408
14.1.12.2	Products/Services offered	408
14.1.12.3	Recent developments	409
14.1.12.3.1	Deals	409
14.1.13	TACONIC BIOSCIENCES, INC.	410
14.1.13.1	Business overview	410
14.1.13.2	Products/Services offered	410
14.1.13.3	Recent developments	412
14.1.13.3.1	Product/Service launches	412
14.1.13.3.2	Deals	413
14.1.13.3.3	Expansions	413
14.1.14	TRANSCURE BIOSERVICES	414
14.1.14.1	Business overview	414
14.1.14.2	Products/Services offered	414
14.1.14.3	Recent developments	415
14.1.14.3.1	Deals	415
14.1.15	VIVO BIO TECH LTD.	416

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.15.1	Business overview	416
14.1.15.2	Product/Services offered	417
14.1.16	INGENIOUS TARGETING LABORATORY	418
14.1.16.1	Business overview	418
14.1.16.2	Product/Services offered	418
14.1.17	JANVIER LABS	420
14.1.17.1	Business overview	420
14.1.17.2	Product/Services offered	420
14.1.17.3	Recent developments	423
14.1.17.3.1	Deals	423
14.1.18	CHAMPIONS ONCOLOGY, INC.	424
14.1.18.1	Business overview	424
14.1.18.2	Products offered	425
14.1.18.3	Recent developments	425
14.1.18.3.1	Deals	425
14.1.19	VITALSTAR BIOTECHNOLOGY CO., LTD.	426
14.1.19.1	Business overview	426
14.1.19.2	Products offered	426
?		
14.2	OTHER PLAYERS	427
14.2.1	ONCODESIGN SERVICES	427
14.2.2	CLEA JAPAN, INC.	428
14.2.3	APPLIED STEMCELL	429
14.2.4	CREATIVE ANIMODEL	430
14.2.5	JOINN LABORATORIES (CHINA) CO., LTD.	431
14.2.6	CREATIVE BIOLABS	432
14.2.7	CRESCENDO BIOLOGICS LIMITED	433
14.2.8	ARAGEN LIFE SCIENCES LTD.	434
14.2.9	POLYGENE	435
14.2.10	PHARMTEST SERVICES	436
14.2.11	MARSHALL BIORESOURCES	437
15	APPENDIX	438
15.1	DISCUSSION GUIDE	438
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	442
15.3	CUSTOMIZATION OPTIONS	444
15.4	RELATED REPORTS	444
15.5	AUTHOR DETAILS	445

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Mice Model Market by Model Type (Inbred, Outbred, Hybrid), Service (Breeding, Rederivation), Application (Personalized Medicine), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology), End User (CROs) - Global Forecast to 2030**

Market Report | 2025-08-12 | 446 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottis-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

Zip Code\*

Country\*

Date

2026-06-09

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)